The announcement risks reviving the debate on the job cuts in the French laboratory, under the blow of criticism for the millions of euros paid to its general manager and a bitter failure concerning the vaccines against the Covid-19. At Sunday newspaper on February 14, 2021, Paul Hudson announced a further delay.
No Sanofi vaccine in 2022
While Pfizer and Moderna have, in a time described as almost miraculous, developed a vaccine against Covid-19 based on RNA technology and Astrazeneca has succeeded, for its part, in creating a vaccine through the technique more traditional development and production, Sanofi… has failed. In 2020, the French pharmaceutical group announces that it will not have a vaccine ready that year: lThe first candidate, based on a recombinant protein, should be finalized before the end of 2021.
But the stampede does not stop there: at Sunday newspaper, February 14, 2021, Paul Hudson reveals that another vaccine, still against Covid-19, is also late and will not be ready before 2022. The clinical trials of its vaccine developed with mRNA technology do not start until this first quarter of 2021… which in no way guarantees that the vaccine will be effective or that it will be authorized to be distributed one day. In the meantime, the Pfizer, Moderna and AstraZeneca vaccines are widely distributed all over the world.
Sanofi bets on the long term: the Covid-19 is gone to stay
If the vaccine race has been lost by Sanofi, the group does not intend to lose the financial windfall that Covid-19 represents: the disease seems to have left to stay, and to become seasonal, a bit like the flu. Vaccination campaigns could therefore take place every year, especially among the most vulnerable populations, all over the world.
Paul Hudson therefore believes that his vaccine “ could prove useful later, especially if the fight against variants were to continue “. The variants, the number of which is multiplying, are the main source of concern regarding Covid-19: some of these mutations could render the vaccines obsolete, which will then have to be reworked.